Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1816 |
Name | angiosarcoma |
Definition | A vascular cancer that derives_from the cells that line the walls of blood vessels or lymphatic vessels. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4508 DOID:267 |
Path | disease disease of cellular proliferation cancer organ system cancer cardiovascular cancer vascular cancer angiosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01396408 | Phase II | Temsirolimus Sunitinib | A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT01446809 | Phase I | Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib | Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01462630 | Phase II | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | Completed | USA | 0 |
NCT02048722 | Phase II | Regorafenib | Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma | Completed | USA | 0 |
NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |
NCT02584309 | Phase II | Dexrazoxane Doxorubicin + Olaratumab | Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02815995 | Phase II | Durvalumab + Tremelimumab | Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes | Completed | USA | 0 |
NCT02979899 | Phase III | Pazopanib Carotuximab + Pazopanib | A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS) | Completed | USA | POL | ITA | GBR | FRA | ESP | DEU | AUT | 0 |
NCT02987959 | Phase II | Sapanisertib | Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | Terminated | USA | 0 |
NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03277924 | Phase Ib/II | Nivolumab + Sunitinib | Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) | Completed | ITA | GBR | ESP | 0 |
NCT03282344 | Phase II | Nivolumab + NKTR-214 | A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03474094 | Phase II | Atezolizumab | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) | Unknown status | GBR | FRA | 0 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT04216953 | Phase Ib/II | Atezolizumab + Cobimetinib | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) | Active, not recruiting | FRA | 0 |
NCT04339738 | Phase II | Cabozantinib + Nivolumab Nivolumab + Paclitaxel Paclitaxel | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | Active, not recruiting | USA | 1 |
NCT04607200 | Phase II | Balstilimab + Zalifrelimab Balstilimab | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma | Withdrawn | 0 | |
NCT04668300 | Phase II | Durvalumab + Oleclumab | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa) | Active, not recruiting | USA | 0 |
NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Recruiting | FRA | 0 |
NCT04784247 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04873375 | Phase II | Cemiplimab | Cemiplimab for Secondary Angiosarcomas | Completed | NLD | 0 |
NCT04906876 | Phase II | Docetaxel + Elraglusib + Gemcitabine | 9-ING-41Combined With Chemotherapy in Adolescents and Adults | Withdrawn | USA | 0 |
NCT04996004 | Phase Ib/II | Doxorubicin + TTI-621 | A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma | Terminated | USA | 0 |
NCT05026736 | Phase II | Sintilimab | Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study | Active, not recruiting | USA | 0 |
NCT05116800 | Phase II | Docetaxel + Elraglusib + Gemcitabine | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Withdrawn | USA | 0 |
NCT05597917 | Phase III | Trabectedin Trabectedin + tTF-NGR | tTF-NGR Randomized Study - STS (TRABTRAP) | Recruiting | DEU | 0 |
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Active, not recruiting | USA | 0 |
NCT05961761 | Phase II | Pembrolizumab + Propranolol | Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients (PROPANE) | Recruiting | SWE | NOR | DNK | 0 |
NCT06021626 | Phase I | CRD3874 | A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer | Recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |
NCT06898970 | Phase II | Pembrolizumab + RP1 | Intratumoral Vusolimogene Oderparepvec (VO) in Combination with Pembrolizumab for Angiosarcoma | Not yet recruiting | USA | 0 |